Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02511405 · ClinicalTrials.gov registry record · Phase 3
A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
A Phase 3 study, sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 252
- Enrollment target
NCT02511405: Completed Phase 3 study, sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics.
NCT02511405 is a Phase 3 study that has completed, run by Vascular Biogenics Ltd. operating as VBL Therapeutics. The registered enrollment target is 252 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02511405, a Phase 3 study, has completed, sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 252 participants
- Enrollment target
Study Summary
The purpose of this pivotal, phase 3, randomized, multicenter study is to compare VB-111 plus bevacizumab to bevacizumab in adult patients with recurrent Glioblastoma.
Interventions
- DRUG Bevacizumab
- DRUG VB-111 + bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2015-08 |
| Est. Completion | 2018-09-30 |
| Phase | Phase 3 |
What the finished NCT02511405 record still lists
NCT02511405 is an interventional study that assigns participants to a tested intervention. The registered 252 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT02511405 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02511405 about?
NCT02511405 is a clinical study titled "A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)". The purpose of this pivotal, phase 3, randomized, multicenter study is to compare VB-111 plus bevacizumab to bevacizumab in adult patients with recurrent Glioblastoma.
What is the current status of trial NCT02511405?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 252 participants. The study started on 2015-08. Estimated completion is 2018-09-30.
What interventions are being tested in trial NCT02511405?
The interventions under investigation include: Bevacizumab (DRUG), VB-111 + bevacizumab (DRUG).
Who is sponsoring clinical trial NCT02511405?
This trial is sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02511405's enrollment target sits among peer trials
252 1246th of 2000 higher than 752 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02314988 · 252 participants · Phase 2
Tranexamic Acid to Reduce Blood Loss in Spine Surgery
- NCT03941756 · 252 participants · NA
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
- NCT05219617 · 252 participants · Phase 3
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
- NCT05384158 · 252 participants · NA
Valuation in Depressed Mood, Anhedonia, and Anxiety
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia